

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ewing et al.

Attorney Docket No.: CAMIP005

Application No.: 09/811,283

Examiner: Not assigned

Filed: March 15, 2001

RECEIVED Group: 1635

Title: PREDICTING METABOLIC STABILITY

OF DRUG MOLECULES

CERTIFICATE OF MELLING I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for

Patents, Washington, DC 20231 on July 13, 2001.

## INFORMATION DISCLOSURE STATEMENT 37 CFR §§1.56 AND 1.97(b)

Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CAMIP005).

Respectfully submitted,

BEXER WEAVER & THOMAS, LLP

Jeffrey K. Weaver

Registration No. 31,314

P.O. Box 778 Berkeley, CA 94704-0778